Kaiser Permanente San Francisco
Claim this profileSummary
Kaiser Permanente San Francisco is a medical facility located in San Francisco, California. This center is recognized for care of Breast Cancer, Lung Cancer, HIV Infection, Human Immunodeficiency Virus Infection, Breast cancer and other specialties. Kaiser Permanente San Francisco is involved with conducting 262 clinical trials across 406 conditions. There are 24 research doctors associated with this hospital, such as Jennifer M. Suga, Tatjana Kolevska, MD, Samantha A. Seaward, and Andrew Rassi, MD.Area of expertise
Breast Cancer
Kaiser Permanente San Francisco has run 46 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Kaiser Permanente San Francisco has run 40 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Jennifer M. Suga
Kaiser Permanente-Oakland
2 years of reported clinical research
Tatjana Kolevska, MD
Kaiser Permanente-Vallejo
2 years of reported clinical research
Samantha A. Seaward
Kaiser Permanente Medical Center - Santa Clara
3 years of reported clinical research
Andrew Rassi, MD
Kaiser Permanente San Francisco
7 years of reported clinical research
Clinical Trials running at Kaiser Permanente San Francisco
Lung Cancer
Ovarian Cancer
Breast Cancer
Cancer
Esophageal cancer
Non-Small Cell Lung Cancer
Breast cancer
Prostate Cancer
Cutaneous Melanoma
Melanoma
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting
2 awards
Phase 3
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting
2 awards
Phase 3
28 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Kaiser Permanente San Francisco?
Kaiser Permanente San Francisco is a medical facility located in San Francisco, California. This center is recognized for care of Breast Cancer, Lung Cancer, HIV Infection, Human Immunodeficiency Virus Infection, Breast cancer and other specialties. Kaiser Permanente San Francisco is involved with conducting 262 clinical trials across 406 conditions. There are 24 research doctors associated with this hospital, such as Jennifer M. Suga, Tatjana Kolevska, MD, Samantha A. Seaward, and Andrew Rassi, MD.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.